Response to Tringali et al., Response to Park et al. on the Clinical Use of Hair Diameter Diversity in Androgenetic Alopecia

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

A 21-year-old woman diagnosed with male pattern baldness (MPB) who is considering treatments such as spironolactone, minoxidil and finasteride to address her hair loss. The user also discusses potential solutions for concealing the appearance of her thinning hair, such as wigs or haircuts.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

A woman's experience with Spironolactone as treatment for female pattern hair loss, including the effects of increasing dosage and her doctor's recommendation to try finasteride if no results are seen after 6 months. Other users have also shared their experiences with using finasteride for this condition.

People worrying about hair loss and the effects of Finasteride on erections, which a transgirl has experienced no change from taking it with other medications. The discussion suggests that people should stop worrying so much.

A user's experience with dealing with hair loss, and the advice that was shared by other users to cope with it. Suggested treatments included shaving their head, using medications such as finasteride, minoxidil, and dutasteride, as well as dermarolling.